ADMA BIOLOGICS DL-,0001

A federal securities lawsuit filed in the U.S. District Court for the District of New Jersey alleges ADMA Biologics inflated revenues for its flagship product through channel stuffing and hid a distribution relationship tied to an entity allegedly controlled by a senior executive. The complaint claims ADMA and certain senior executives made materially false statements about revenue growth, internal controls and related-party transactions, following a March short-seller report by Culper Research. ADMA shares plunged in late March after the short report, and recent analyst coverage resumed with a bullish outlook despite the legal scrutiny. » More on finance.yahoo.com

FDA approved an expanded indication for ADMA Biologics' ASCENIV to treat pediatric patients aged two years and older, down from the previous 12‑year threshold, following a post‑marketing pediatric assessment. The company will prioritize ASCENIV for earlier pediatric care, a milestone CEO Adam Grossman said enables treatment of younger immune‑compromised patients. ASCENIV is a plasma‑derived intravenous immune globulin produced using ADMA’s donor screening and pooling methods. » More on finance.yahoo.com

ADMA Biologics reported Q1 2026 EPS of $0.19 (forecast $0.20) and revenue of $114.5 million, well below the expected $142.74 million. Strong growth in ASCENIV (+28% year-over-year) was offset by a decline in BIVIGAM (-54%); gross margin was 71% and adjusted EBITDA rose 24%. The stock reacted only mildly negative and recovered in after-hours trading; management emphasizes expanding sales and capacity but sees ongoing competition and pricing pressure as the main risks. » More on de.investing.com

ADMA Biologics responded to a report by Culper Research that disclosed a short position, calling the statements misleading, false and based on anonymous speculation. The company is reviewing the allegations and emphasizes its commitment to accurate reporting under SEC and US-GAAP requirements. ADMA notes it remains profitable, generated $510 million in revenue over the past twelve months, and manufactures three FDA-approved plasma biologics. » More on de.investing.com

ADMA Biologics' stock fell more than 9% after the publication of a report by Culper Research accusing the company of artificially inflating revenue growth through channel stuffing. Culper claims that without these practices, revenues in 2025 would have declined by 3% rather than rising by 20%, and points to large discrepancies between third-party sales data and the revenues reported by ADMA. The report cites an increase in days sales outstanding from 43 to 113, high revenue and receivables concentration with two distributors, and adjusted EBITDA far exceeding operating cash flow as indications of questionable business practices. » More on de.investing.com